key: cord-0866001-1jjbytdt
authors: Salvagno, Gian Luca; Henry, Brandon M.; Pighi, Laura; De Nitto, Simone; Gianfilippi, Gian Luca; Lippi, Giuseppe
title: Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
date: 2021-06-30
journal: J Infect
DOI: 10.1016/j.jinf.2021.06.024
sha: 3b1cc47a1b104bebe670f522f9ab248d1555054b
doc_id: 866001
cord_uid: 1jjbytdt

nan

The study population consisted of healthcare workers undergoing voluntary vaccination with Pfizer BNT162b2 mRNA COVID-19 vaccine (Comirnaty; Pfizer Inc, NY, USA) at the hospital of Peschiera del Garda (Italy). All subjects received two 30 μg BNT162b2 vaccine doses, 3 weeks apart. Blood was collected immediately before receiving the first vaccine dose, immediately before receiving the second vaccine dose (i.e., 21 days after the first dose), as well as 50 days and 3 months after the first vaccine dose, via a previously specified protocol. 2 Serum was separated by centrifugation for 15 min at 1500×g at room temperature, divided in aliquots and stored at -70°C until measurement. Total anti-SARS-CoV-2 antibodies were assayed using the Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay, on a Roche Cobas 6000 (Roche Diagnostics, Basel, Switzerland). This method was found to have good correlation and agreement with a pseudovirus neutralizing test (r=0.58; Cohen's kappa, 0.60). 3 The statistical analysis was conducted using Analyse-it (Analyse-it Software Ltd, Leeds, UK), with results of measurements expressed as median and interquartile range (IQR). Comparisons between groups were carried out with Mann-Whitney test or In conclusion, the results of our study extend the evidence provided by Tré-Hardy et al. 1 that total anti-SARS-CoV-2 S antibodies levels tend to decline at 3 months after the first vaccine dose, though we also showed that such decline occurs in both baseline seropositive and seronegative subjects, and with serum levels that tend to be significantly lower in older subjects. These findings not only confirm the importance of serological testing for monitoring the immunogenic response after vaccination, 4 but provide further support to the conclusion that personalization of COVID-19 vaccine 4 administration, with use of further boosters, may be advisable in selected categories of the population.

The study protocol (number 3246CESC) was cleared by the Ethics Committee of the Provinces of Verona and Rovigo. All subjects were informed of the study and voluntarily agreed to participate, providing a written consent).

Gianfilippi. Investigation: All. Acquisition, analysis, interpretation of data and visualization: All. Supervision and manuscript-first draft: Giuseppe Lippi. Critical revision of the manuscript: Brandon M. Henry.

None declared.

The authors have no relevant competing interest to disclose in relation to this work. 

Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?

The authors are thankful to the entire staff of the Pederzoli Hospital of Peschiera del Garda (Verona, Italy) for accepting to participate to this study.